Shots:

• The US FDA has approved Xeljanz XR extended-release (11 & 22mg- qd) for the treatment of mod. to sev. active UC- after an inadequate response or intolerance to TNF blockers
• Pfizer will advance the science of JAK inhibition and enhance the understanding of Xeljanz XR via robust clinical development programs in the treatment of immune-mediated inflammatory conditions
• Xeljanz XR (qd) is the first and only JAK inhibitor- which allows patients living with mod. to sev. active UC to manage their disease and has received approval in 130+ countries for moderately to severely active RA- UC- and PsA

Click here to­ read full press release/ article | Ref: Pfizer | Image: Behance